全文获取类型
收费全文 | 47571篇 |
免费 | 4665篇 |
国内免费 | 1219篇 |
专业分类
耳鼻咽喉 | 257篇 |
儿科学 | 1986篇 |
妇产科学 | 303篇 |
基础医学 | 5189篇 |
口腔科学 | 680篇 |
临床医学 | 5209篇 |
内科学 | 12297篇 |
皮肤病学 | 214篇 |
神经病学 | 1154篇 |
特种医学 | 2617篇 |
外国民族医学 | 1篇 |
外科学 | 4062篇 |
综合类 | 7360篇 |
现状与发展 | 3篇 |
预防医学 | 4094篇 |
眼科学 | 247篇 |
药学 | 4124篇 |
27篇 | |
中国医学 | 2397篇 |
肿瘤学 | 1234篇 |
出版年
2024年 | 45篇 |
2023年 | 1016篇 |
2022年 | 1386篇 |
2021年 | 1701篇 |
2020年 | 1737篇 |
2019年 | 1533篇 |
2018年 | 1718篇 |
2017年 | 1490篇 |
2016年 | 1780篇 |
2015年 | 2208篇 |
2014年 | 3252篇 |
2013年 | 3299篇 |
2012年 | 2926篇 |
2011年 | 2840篇 |
2010年 | 2524篇 |
2009年 | 2464篇 |
2008年 | 2384篇 |
2007年 | 2277篇 |
2006年 | 2022篇 |
2005年 | 1807篇 |
2004年 | 1796篇 |
2003年 | 1111篇 |
2002年 | 922篇 |
2001年 | 886篇 |
2000年 | 632篇 |
1999年 | 590篇 |
1998年 | 602篇 |
1997年 | 623篇 |
1996年 | 541篇 |
1995年 | 550篇 |
1994年 | 654篇 |
1993年 | 446篇 |
1992年 | 464篇 |
1991年 | 428篇 |
1990年 | 412篇 |
1989年 | 303篇 |
1988年 | 322篇 |
1987年 | 216篇 |
1986年 | 216篇 |
1985年 | 226篇 |
1984年 | 203篇 |
1983年 | 99篇 |
1982年 | 210篇 |
1981年 | 144篇 |
1980年 | 100篇 |
1979年 | 86篇 |
1978年 | 70篇 |
1977年 | 67篇 |
1976年 | 42篇 |
1975年 | 28篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
《Revista portuguesa de cardiologia》2022,41(9):783-789
Amiodarone is the most potent antiarrhythmic drug available and is commonly prescribed to treat and prevent not only life-threatening ventricular arrhythmias but also atrial fibrillation (AF). The latest European Society of Cardiology AF guidelines state that amiodarone is recommended for long-term rhythm control in all AF patients but that other antiarrhythmic drugs should be considered first whenever possible, due to its extracardiac toxicity. In patients without significant or with only minimal structural heart disease, amiodarone is not listed as a possibility in their therapeutic scheme. Still, amiodarone is widely and liberally used, and is the most prescribed antiarrhythmic drug for patients with AF despite its high toxicity profile. Non-cardiovascular death was more frequent with amiodarone treatment than with a rate control strategy in AFFIRM, while meta-analyses suggest an association between amiodarone use in patients without structural heart disease and increased non-cardiovascular mortality. Severe or even fatal outcomes due to amiodarone may occur years after treatment initiation and are often not acknowledged by the prescribing physician, who may no longer be following the patient. The lack of widely accepted diagnostic criteria and symptom definitions may lead to underestimation of the incidence of severe side effects and of its toxicity. Unlike the underestimated risk of toxicity with amiodarone, severe complications associated with catheter ablation are usually directly ascribed to the treatment even by non-medical personnel, possibly resulting in overestimation of risks. This brief review will address the issue of amiodarone overuse and the frequent underestimation of its toxicity, while suggesting scenarios in which its use is entirely reasonable, and compare it with catheter ablation. 相似文献
2.
3.
4.
5.
6.
7.
目的 通过分析特发性肺纤维化急性加重期(AE-IPF)患者证候与血清生物标志物的关系,为中医辨证治疗提供参考。方法 采用观察性研究设计,收集2019年3月至2019年11月三个中心的AE-IPF患者76例,其中痰热壅肺证26例、痰浊阻肺证50例,并纳入健康志愿者10例作为对照。采用ELISA测定患者血清CCL18、HMGB1、KL-6、MMP-7、SP-A和SP-D水平,分析与中医证候的相关性。结果 AE-IPF患者血清CCL18、HMGB1、KL-6、MMP-7、SP-A和SP-D水平均显著高于健康对照组。血清CCL18、HMGB1、KL-6、MMP-7和SP-D水平在痰热壅肺证和痰浊阻肺证患者间无显著性差异(P>0.05),而血清SP-A水平存在显著性差异(P<0.05)。结论 血清SP-A与AE-IPF证候存在一定的相关性,血清SP-A的浓度升高,与痰热壅肺证关系越密切,反之,血清SP-A浓度降低,则与痰浊阻肺证关系越密切。AE-IPF痰热壅肺证患者的预后可能较痰浊阻肺证患者更差。 相似文献
8.
Efficacy of Curcumin in Combination with Intralesional Dexamethasone with Hyaluronidase in the Treatment of Oral Submucous Fibrosis: A Randomized Controlled Trial 下载免费PDF全文
Sagar AdhikariJyotsna RimalIccha Kumar MaharjanAshish Shrestha 《Asian Pacific journal of cancer prevention》2022,23(9):3125-3132
Objective: The objective of this study was to determine the efficacy of curcumin in combination with intralesional dexamethasone with hyaluronidase in the treatment of oral submucous fibrosis (OSF). Methods: This randomized, double blind, parallel design, clinical trial was conducted at B.P. Koirala Institute of Health Sciences, Nepal. Thirty-four patients with clinically diagnosed OSF were randomized into two groups (17 participants in each) with baseline treatment of intralesional dexamethasone with hyaluronidase for 6 weeks for the both. Curcumin (2gm/day) was provided to Group A (Test) and Group B (Control) received placebo. Interincisal mouth opening, tongue protrusion, cheek flexibility and visual analogue scale (VAS) scoring of burning sensation of oral mucosa was recorded at baseline, 6, 8 and 12 weeks follow-up and independent t-test was used to compare the improvements in two groups. Results: On comparing the 6 weeks and baseline values, in Group A and B the mean difference in mouth opening was 8.82±1.33 mm and 5.53±1.17 mm respectively (p<0.001), in cheek flexibility was 2.94±1.02 mm and 1.94±1.24 mm respectively (p=0.02) and in tongue protrusion was 6.23±1.48 and 3.65±1.37 mm respectively (p<0.001). The findings were consistent in the 8 weeks follow-up. In 12 weeks follow-up, on comparing with the baseline values, in Group A and B, the mean difference in mouth opening was 8.71±1.16 mm and 5.35±1.22 mm respectively (<0.001), ), in cheek flexibility was 2.81±1.01 mm and 1.76±1.35 mm respectively (p=0.02) and in tongue protrusion was 6.06±1.48 and 3.35±1.50 mm respectively (p<0.001). Both the arms showed 100% improvement in burning sensation in 6, 8 and 12 weeks follow-up. Conclusion: Curcumin in combination with intralesional dexamethasone with hyaluronidase is efficacious in the treatment of OSF. 相似文献